How to buy AC Immune stock

AC Immune SA is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. AC Immune employs 125 staff and has a trailing 12-month revenue of around 0.00.

AC Immune share price

Use our graph to track the performance of ACIU stocks over time.

AC Immune shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$4.42 - $9.45
50-day moving average	$7.31
200-day moving average	$6.27
Wall St. target price	$13.96
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.55

Buy AC Immune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AC Immune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of AC Immune SA by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AC Immune financials

Revenue TTM	$3.2 million
Gross profit TTM	$-44,056,000
Return on assets TTM	-17.24%
Return on equity TTM	-30.01%
Profit margin	0%
Book value	$2.85
Market capitalisation	$497.3 million

TTM: trailing 12 months

Shorting AC Immune shares

There are currently 1.3 million AC Immune shares held short by investors – that's known as AC Immune's "short interest". This figure is 8.1% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting AC Immune shares can be evaluated.

AC Immune's "short interest ratio" (SIR)

AC Immune's "short interest ratio" (SIR) is the quantity of AC Immune shares currently shorted divided by the average quantity of AC Immune shares traded daily (recently around 251103.07692308). AC Immune's SIR currently stands at 5.2. In other words for every 100,000 AC Immune shares traded daily on the market, roughly 5200 shares are currently held short.

However AC Immune's short interest can also be evaluated against the total number of AC Immune shares, or, against the total number of tradable AC Immune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AC Immune's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AC Immune shares in existence, roughly 20 shares are currently held short) or 0.041% of the tradable shares (for every 100,000 tradable AC Immune shares, roughly 41 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AC Immune.

Find out more about how you can short AC Immune stock.

AC Immune share dividends

We're not expecting AC Immune to pay a dividend over the next 12 months.

AC Immune share price volatility

Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.42 up to $9.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.7994. This would suggest that AC Immune's shares are less volatile than average (for this exchange).

AC Immune overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.

Frequently asked questions

• What percentage of AC Immune is owned by insiders or institutions?

  Currently 51.342% of AC Immune shares are held by insiders and 29.162% by institutions.

• How many people work for AC Immune?

  Latest data suggests 125 work at AC Immune.

• When does the fiscal year end for AC Immune?

  AC Immune's fiscal year ends in December.

• Where is AC Immune based?

  AC Immune's address is: Building B, Lausanne, Switzerland, 1015

• What is AC Immune's ISIN number?

  AC Immune's international securities identification number is: CH0329023102

• What is AC Immune's CUSIP number?

  AC Immune's Committee on Uniform Securities Identification Procedures number is: H00263105